| Expression pattern: |
UP |
| Associated gene: |
YTHDC2, m6A |
| Associated microRNA: |
- |
| Biological function: |
Associated with aggressive tumor features and shorter progression-free survival; functions as a stable diagnostic and prognostic biomarker in LIHC. |
| Molecular mechanism: |
YTHDC2 binds circYTHDC2 and enhances its stability via m6A modification (m6A-dependent regulation). |
| Biological pathway or process: |
m6A modification (promotes); mRNA stability (promotes); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; Clinical Sample Validation; Survival Analysis; ROC Analysis |
| Clinical significance: |
High diagnostic accuracy in tissues and serum (ROC AUC 0.846 and 0.788); high expression correlates with advanced BCLC stage, larger tumor size, intrahepatic metastasis, portal invasion, and shorter progression-free survival. |
| Description: |
CircYTHDC2 is up-regulated in LIHC tissues, patient serum, and LIHC cell lines and shows diagnostic value by ROC analysis. High CircYTHDC2 correlates with aggressive clinicopathological features and shorter progression-free survival. Mechanistically, YTHDC2 binds CircYTHDC2 and increases its stability through an m6A-dependent process. |
| Confidence score: |
0.7875 |